Literature DB >> 19091321

Simple and precise detection of lipid compounds present within liposomal formulations using a charged aerosol detector.

Carina Schönherr1, Sounia Touchene, Gaston Wilser, Regine Peschka-Süss, Giancarlo Francese.   

Abstract

In recent decades the use of liposomal preparations as drug delivery systems has become very attractive in pharmaceutical development. Therefore, thorough characterization and quantification of the lipids which form liposomes is wished from both investigators and regulatory authorities when the application in humans is being considered. In this study a new HPLC method for the detection of lipids in liposomal formulations was established using corona charged aerosol detection (CAD) which has the advantage to be independent of the chemical properties of the analytes. The superiority of this method over UV detection was demonstrated. Compared to UV detection no absorption effects of the organic solvent in the mobile phase interfering with the lipid signals were observed with CAD. CAD showed good linearity (R(2)>0.990) for all liposomal compounds. The acceptance criteria for precision including repeatability were met. The average recovery for each of the excipients of the liposomal formulation was in the range of 90.0-110%.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19091321     DOI: 10.1016/j.chroma.2008.11.080

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  3 in total

1.  Simple chromatographic method for simultaneous analyses of phosphatidylcholine, lysophosphatidylcholine, and free fatty acids.

Authors:  Abebe Endale Mengesha; Paul M Bummer
Journal:  AAPS PharmSciTech       Date:  2010-06-29       Impact factor: 3.246

2.  Simultaneous determination of polyethylene glycol-conjugated liposome components by using reversed-phase high-performance liquid chromatography with UV and evaporative light scattering detection.

Authors:  Hiroko Shibata; Chikako Yomota; Haruhiro Okuda
Journal:  AAPS PharmSciTech       Date:  2013-04-23       Impact factor: 3.246

3.  Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906).

Authors:  Karine Scherzinger-Laude; Carina Schönherr; Felicitas Lewrick; Regine Süss; Giancarlo Francese; Jochen Rössler
Journal:  Int J Nanomedicine       Date:  2013-06-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.